[go: up one dir, main page]

WO2012138911A3 - Conjugates of anti-hiv drugs and somatostatin analogs - Google Patents

Conjugates of anti-hiv drugs and somatostatin analogs Download PDF

Info

Publication number
WO2012138911A3
WO2012138911A3 PCT/US2012/032402 US2012032402W WO2012138911A3 WO 2012138911 A3 WO2012138911 A3 WO 2012138911A3 US 2012032402 W US2012032402 W US 2012032402W WO 2012138911 A3 WO2012138911 A3 WO 2012138911A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
somatostatin analogs
hiv drugs
hiv
somatostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/032402
Other languages
French (fr)
Other versions
WO2012138911A2 (en
Inventor
Debasis MONDAL
Christine BULOT
Joseph Fuselier
David Coy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Publication of WO2012138911A2 publication Critical patent/WO2012138911A2/en
Publication of WO2012138911A3 publication Critical patent/WO2012138911A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention features conjugates of a somatostatin analog and anti-HIV agent (e.g., an HIV protease inhibitor (HPI), such as nelfinavir), and their use in the treatment of a patient (e.g., a human) infected with HIV.
PCT/US2012/032402 2011-04-05 2012-04-05 Conjugates of anti-hiv drugs and somatostatin analogs Ceased WO2012138911A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161516581P 2011-04-05 2011-04-05
US61/516,581 2011-04-05

Publications (2)

Publication Number Publication Date
WO2012138911A2 WO2012138911A2 (en) 2012-10-11
WO2012138911A3 true WO2012138911A3 (en) 2012-12-27

Family

ID=46969827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/032402 Ceased WO2012138911A2 (en) 2011-04-05 2012-04-05 Conjugates of anti-hiv drugs and somatostatin analogs

Country Status (1)

Country Link
WO (1) WO2012138911A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102062025B1 (en) * 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 Targeted conjugates and particles and formulations thereof
WO2017075495A1 (en) 2015-10-28 2017-05-04 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
CN115697328A (en) * 2020-03-23 2023-02-03 约翰·M.H.·格雷格 Antiviral compounds and methods of administration thereof
EP4188546A4 (en) * 2020-07-28 2024-08-07 Cytocom Inc. TREATMENT OF VIRAL DISEASES
US20240398969A1 (en) * 2023-06-01 2024-12-05 Taimed Biologics Inc. Antibody-drug conjugates for treating infections of human immunodeficiency virus (hiv)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324700A (en) * 1997-03-28 1998-12-08 Seikagaku Kogyo Co Ltd New anti-hiv conjugate and medicinal composition
US20010029035A1 (en) * 2000-02-14 2001-10-11 Michael Eisenhut Oligonucleotide conjugates
US20060193865A1 (en) * 2002-12-13 2006-08-31 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US20080103094A1 (en) * 2001-05-15 2008-05-01 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10324700A (en) * 1997-03-28 1998-12-08 Seikagaku Kogyo Co Ltd New anti-hiv conjugate and medicinal composition
US20010029035A1 (en) * 2000-02-14 2001-10-11 Michael Eisenhut Oligonucleotide conjugates
US20080103094A1 (en) * 2001-05-15 2008-05-01 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of viral infections
US20060193865A1 (en) * 2002-12-13 2006-08-31 Immunomedics, Inc. Camptothecin-binding moiety conjugates

Also Published As

Publication number Publication date
WO2012138911A2 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
NZ718708A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1208150A1 (en) Vaccine
PH12015502539A1 (en) Cenicriviroc compositions and methods of making and using the same
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501156A1 (en) Pharmaceutical compositions
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
PH12015500115B1 (en) Glucagon analogues
WO2012047856A3 (en) Novel inhibitors of secretion of hepatitis b virus antigens
UA105556C2 (en) Combination of compounds comprising hiv integrase inhibitors with other therapeutical agents
MX2019003249A (en) Diagnosis, prevention and treatment of diseases of the joint.
PH12014500386A1 (en) Combination treatment for hepatitis c
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
EP4414376A3 (en) Novel depsipeptide and uses thereof
ES2524385R1 (en) Pharmaceutical composition and its use to prepare a medicine for the treatment and prevention of HIV diseases
EA201171186A1 (en) SOKRISTALL ETRAVIRIN AND NICOTINAMIDE
MX343505B (en) Methods and compositions for inhibiting hiv transmission.
GB2498276B (en) Medicinal agent and mode of prevention of HIV contamination, prevention and treatment of diseases caused by HIV and HIV-associated diseases including AIDS.
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
WO2012138911A3 (en) Conjugates of anti-hiv drugs and somatostatin analogs
MX2013003245A (en) Bvdv vaccine.
GB201014391D0 (en) Drug composition and its use in therapy
UA118474C2 (en) (S) -PIRLINDOL AND ITS PHARMACEUTICALLY ACCEPTED SALTS FOR MEDICINAL USE
WO2015086738A3 (en) Hiv vaccine
MX364652B (en) Pharmaceutical formulation comprising ciclesonide.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12768228

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12768228

Country of ref document: EP

Kind code of ref document: A2